Survival analysis from a TCGA data set (seen in PATIENTS AND METHODS) found that the AML patients with lower DNMT3A expression showed significantly shorter median OS than those with higher DNMT3A expression (lower DNMT3A: 335 days vs higher DNMT3A: 822 days, P<0.001, Figure 6). This evidence concerns the gene DNMT3A and acute myeloid leukemia.